The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.

A nutritional composition for a subject, comprising prolactin identical or similar or analogous to prolactin found in a natural food source, and at least one protective layer, wherein release of said prolactin from the composition in said subject is the result of an environmental event.

A system and method for tuning hormone receptors through the dynamic intravenous introduction of a hormone in a manner that mimics a target physiological secretion cadence of that hormone is presented herein. In particular, a dosing model is developed with a desired goal of creating a hormone delivery plan with a dosing waveform that resembles a waveform associated with the target physiological secretion cadence of the hormone. Several bolus delivery specifications, including volume, frequency and pressure, are dynamically defined such that, over a specified period of time, the bolus introductions create the desired dosing waveform. The dosing model is then executed through a plurality of successive and dynamic intravenous exogenous bolus introductions of the hormone according to the plurality of bolus delivery specifications.

The present disclosure relates to the use of C-terminal fragments of human and non-human growth hormone, synthetic cyclic peptides and C-terminal fragments of human prolactin precursor for the treatment of inflammatory airway disease in a subject in need thereof.

A system and method for tuning hormone receptors through the dynamic intravenous introduction of a hormone in a manner that mimics a target physiological secretion cadence of that hormone is presented herein. In particular, a dosing model is developed with a desired goal of creating a hormone delivery plan with a dosing waveform that resembles a waveform associated with the target physiological secretion cadence of the hormone. Several bolus delivery specifications, including volume, frequency, and pressure, are dynamically defined such that, over a specified period of time, the bolus introductions create the desired dosing waveform. The dosing model is then executed through a plurality of successive and dynamic intravenous exogenous bolus introductions of the hormone according to the plurality of bolus delivery specifications.